New Drug Reverses Anticoagulant Effects of Blood Thinner
News Jul 16, 2015
Dabigatran, sold under the brand name Pradaxa, is a blood-thinner used to prevent strokes in patients with the heart condition atrial fibrillation.
The study enrolled 90 patients at 184 sites in 35 countries, including Northwestern Medicine. Unlike warfarin, but similarly to other members of the class of Novel Oral Anticoagulants, there are no currently approved reversal agents for dabigatran.
“Dabigatran prevents strokes better than warfarin with less bleeding in the brain, but one problem with dabigatran and other novel anticoagulants was that there was no reversal agent,” said Richard A Bernstein, MD, PhD, a co-author and professor in Neurology – Ken and Ruth Davee Department. “Some clinicians were wary of using this class of medications because there was no way to turn it off.”
Idarucizumab is given intravenously and binds to dabigatran. Within minutes of administration, the anticoagulant effect of dabigatran was completely reversed in the first 90 patients enrolled in this study.
“The advent of this reversal agent should provide both patients and physicians with peace of mind when taking dabigatran,” Dr. Bernstein said. “Its always good to have a way to turn off the effect of this blood thinner in emergencies.”
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018